MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial
PR Newswire•12/11/2026•08:31 ET
0
Key Highlights
- ➤DA-1726 cut uric acid 1.47 mg/dL placebo-adjusted after 16 weeks (p<0.001)
- ➤DA-1726 delivered 68.1% placebo-adjusted liver-fat reduction (p<0.001)
- ➤DA-1726 produced 13.5% placebo-adjusted weight loss (p<0.001)
- ➤All five DA-1726-treated subjects with baseline steatosis normalized liver fat
- ➤MetaVia plans Phase 2 MetALD/ALD study in second half of 2027
Expert Statements
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“These additional findings further strengthen the metabolic profile emerging for DA-1726 and provide another encouraging signal as we advance its development in liver-related cardiometabolic diseases.”
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“The statistically significant reduction in uric acid is particularly noteworthy given that participants entered the study with mean levels already within the normal range.”
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“Elevated uric acid has been associated with liver fat accumulation, insulin resistance and alcohol consumption, making these findings particularly relevant to our focus on MetALD and ALD.”
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“Combined with the previously reported significant reductions in liver fat, body weight and HbA1c, these results reinforce our belief that DA-1726 has the potential to deliver benefits beyond weight loss alone.”
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“We believe the dual GLP-1 and glucagon receptor agonism of DA-1726, together with the robust effects observed across multiple metabolic parameters, provides a compelling foundation for further clinical development.”
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“We expect to report full data from Part 3A and Part 3B in the first quarter of 2027 and are planning a 48-week, non-biopsy Phase 2 study in up to 150 subjects with MetALD and ALD, targeted to begin in the second half of 2027.”
MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial PR Newswire
Adding to Previously Reported 68.1% Liver Fat Reduction and Strengthening Its Liver Profile for MetALD
Get started
Create a free account to read the full story.